Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine.
Several strategies are being examined to enhance the potency of DNA rabies vaccine (DRV) so that it can be used for both prophylaxis and postexposure therapy of rabies. In this study, we report a novel combination rabies vaccine (CRV) containing a low dose of cell culture-derived inactivated rabies virus vaccine and DRV. Mice immunized with CRV develop higher levels of rabies virus-neutralizing antibodies (RVNA) than those immunized with DRV and are completely protected against peripheral as well as intracerebral rabies virus challenge. The quantity of inactivated rabies virus vaccine required for enhancing the potency of DRV can be 625-fold lower than that of a standard dose of inactivated rabies virus vaccine. CRV induces higher levels of RVNA than DRV in cattle as well. Thus, we demonstrate for the first time that co-inoculation of DNA vaccine and a low dose of inactivated virus vaccine can be developed into a novel cost-effective vaccination strategy for combating rabies in particular, and infectious diseases in general.
Biswas
S
S
Department of Biochemistry, Indian Institute of Science, Bangalore 560012, India.
Reddy
G S
GS
Srinivasan
V A
VA
Rangarajan
P N
PN
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D018076:DNA, Complementary / Q000378:metabolism; D007700:Kinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids / Q000378:metabolism; D011818:Rabies / Q000517:prevention & control* / Q000628:therapy*; D011819:Rabies Vaccines / Q000235:genetics* / Q000276:immunology*; D011820:Rabies virus / Q000235:genetics*; D019444:Vaccines, DNA / Q000627:therapeutic use*; D015164:Vaccines, Inactivated / Q000276:immunology*
D000914:Antibodies, Viral; D018076:DNA, Complementary; D011819:Rabies Vaccines; D019444:Vaccines, DNA; D015164:Vaccines, Inactivated